Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual FilmGlobeNewsWire • 12/05/23
Aquestive Therapeutics (AQST) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 11/29/23
Aquestive Therapeutics (AQST) Is Up 2.98% in One Week: What You Should KnowZacks Investment Research • 11/27/23
Aquestive Therapeutics (AQST) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 11/16/23
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual MeetingGlobeNewsWire • 11/10/23
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/23
Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 11/01/23
Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 10/24/23
ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In BothSeeking Alpha • 09/22/23
Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual FilmGlobeNewsWire • 09/20/23
Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should KnowZacks Investment Research • 09/13/23
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/23